Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
02 11월 2023 - 8:00PM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, today
announced it is joining advocacy organizations around the world to
help raise awareness of Alzheimer’s disease (AD) and to stand in
solidarity with all those affected by this condition and their
families during Alzheimer’s Disease Awareness Month. November marks
Alzheimer’s Disease Awareness Month, an important time to know the
facts about this illness that affects millions.
On November 2, Axsome’s headquarters at One
World Trade Center, New York City, will be lit in teal as part of
the Alzheimer’s Foundation of America’s (AFA) “Light the World in
Teal” campaign. More than 1,000 structures around the world to “Go
Teal” as part of this campaign. The color teal is used by the AFA
as a symbol of awareness and support for this devastating illness.
Throughout the month, AFA also encourages people to “Go Teal” by
dressing in the color to show support for AD awareness. You can
learn more about the AFA’s awareness campaign and find resources
and networks for AD support at their website here.
AD is a progressive neurodegenerative disorder
characterized by cognitive decline, and behavioral and
psychological symptoms including agitation. AD is the most common
form of dementia and afflicts an estimated 6 million individuals
in the United States, a number that is anticipated to increase
to approximately 14 million by 2050.1 It is a leading cause of
death in older adults, and exacts an emotional, physical, and
financial toll on the entire family of those who are diagnosed.
These facts highlight the significant need for additional research
into innovative treatment approaches to help people with AD and
their loved ones live better lives.
For more information about AD as well as to
learn more about organizations and their affiliates that provide
resources and support networks for Alzheimer’s communities, please
read more here:
- Alzheimer’s Foundation of
America (AFA) (https://alzfdn.org/). AFA provides support,
services and education to individuals, families and caregivers
affected by Alzheimer’s disease and related dementias nationwide,
and funds research for better treatment and a cure.
- Alzheimer’s
Association (https://www.alz.org/). The Alzheimer's
Association leads the way to end Alzheimer's and all other dementia
by accelerating global research, driving risk reduction and early
detection, and maximizing quality care and support.
-
UsAgainstAlzheimer's
(https://www.usagainstalzheimers.org/). UsAgainstAlzheimer’s was
founded in 2010 to disrupt and diversify the movement to cure
Alzheimer’s. Through urgent and inclusive mobilization,
UsAgainstAlzheimer’s works to dramatically increase funding for
Alzheimer’s and dementia research.
- CaringKind
(https://www.caringkindnyc.org/). CaringKind is New York City’s
leading expert on Alzheimer’s and dementia caregiving. With over 40
years of experience, CaringKind works directly with community
partners to develop the information, tools and training to support
individuals and families affected by dementia.
- Alzheimer’s Orange
County (https://www.alzoc.org/). Since 1982, Alzheimer’s
Orange County has been Orange County’s center for Alzheimer’s
resources. They are dedicated to providing quality care and support
services to the thousands of residents of Orange County who are
affected by Alzheimer’s disease or other related dementia, and also
partnering with local researchers to populate clinical trials to
help find a cure.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected revenues or expenses), futility
analyses and receipt of interim results, which are not necessarily
indicative of the final results of our ongoing clinical trials,
and/or data readouts, and the number or type of studies or nature
of results necessary to support the filing of a new drug
application (“NDA”) for any of our current product candidates; our
ability to fund additional clinical trials to continue the
advancement of our product candidates; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration
(“FDA”) or other regulatory authority approval of, or other action
with respect to, our product candidates, including statements
regarding the timing of any NDA submission; whether issues
identified by FDA in the complete response letter may impact the
potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, if
approved, and the potential impact on the Company’s anticipated
cash runway; unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contacts:
Investors:Mark JacobsonChief Operating
OfficerAxsome Therapeutics, Inc.One World Trade Center, 22nd
FloorNew York, NY 10007Tel: 212-332-3243Email: mjacobson@axsome.com
www.axsome.com
Media:
Darren OplandDirector, Corporate
CommunicationsAxsome Therapeutics, Inc.One World Trade Center, 22nd
FloorNew York, NY 10007Tel: 929-837-1065Email: dopland@axsome.com
www.axsome.com
References:
- Alzheimer’s Association. 2020
Alzheimer’s Disease Facts and Figures. Alzheimers Dement
2020;16(3):391+.
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024